McCormick & Company, Incorporated (MKC) Income Statement

The top-line trajectory shows a genuine inflection from contraction in 2024 to high-teens growth in 2026, but the magnitude and speed of the acceleration, coinciding with the flagged pending merger activity, suggests inorganic revenue is a material contributor that organic momentum alone may not support. Critically, the growth has not translated into earnings momentum: sequential EPS of $0.36 versus $0.56 a quarter earlier implies the incremental revenue is being acquired at low or negative incremental margins, raising questions about the durability and quality of this growth path.

The gross margin resilience, roughly 15-20 points above the HRL and THS peers in the comparison set, appears consistent with a pricing and brand portfolio that retains shelf-space leverage despite a decelerating packaged-food backdrop. However, the widening gap between gross margin stability and operating margin erosion indicates the problem lies downstream of production economics, most plausibly in trade promotion intensity and overhead absorption. Investors should note that 2026Q3's 10.7% operating margin is the lowest print in the ten-quarter history, which, if sustained, would signal a structural rather than cyclical repricing of the business.

For a business that historically exhibits positive operating leverage given high gross margins, the current configuration is anomalous: gross profit grew roughly $150M year over year in the third quarter, yet operating income declined by about $70M, implying incremental spend consumed well over 100% of incremental gross profit. The seasonal SG&A pattern, heavier in Q4 and Q1, appears normal, but the 2026 run-rate sits higher than 2025 equivalents in comparable quarters, suggesting overhead tied to integration or acquisition build-out may be persisting. This warrants monitoring, as an adverse leverage trend directly undermines the premium multiple the market typically assigns to flavor-science franchises.

The COGS trajectory is the cleaner signal in the statement: the ratio has been broadly stable, suggesting the company has largely passed through raw agricultural input volatility, including commodity exposure to vanilla and pepper, without structural margin sacrifice. The more ambiguous area is SG&A, where the 2026 Q2/Q3 levels exceed 2025 comparables by roughly 20-25%, indicating that spending is not being scaled down as revenue mix shifts. Because R&D appears as zero rather than reported as absent, no judgment can be formed on whether innovation investment is being capitalized, bundled into other lines, or simply not captured here, and that gap matters for a company whose moat claim rests on flavor-science capability.